CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
嘌呤能通路及其在急性髓系白血病治疗中的临床应用
英文原题：Purinergic pathways and their clinical use in the treatment of acute myeloid leukemia.
查看英文原题
Purinergic pathways and their clinical use in the treatment of acute myeloid leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管使用了造血干细胞移植和CAR-T 细胞疗法（CAR-T）等多种治疗方法，急性髓系白血病（AML）患者的预后仍然普遍较差。然而，免疫治疗目前是血液肿瘤治疗的热点。细胞外三磷酸腺苷（ATP）可通过CD39转化为二磷酸腺苷（ADP），ADP可通过CD73转化为腺苷，腺苷可与P1和P2受体结合发挥免疫调节作用。对嘌呤能信号通路机制的研究可为AML的治疗提供新方向，该信号通路的抑制剂已被多位研究者发现并逐渐应用于临床。本文阐述了嘌呤能信号通路的机制及其临床应用，揭示了治疗AML并随后改善患者预后的新靶点。
展开英文摘要原文
Despite the use of various therapies such as hematopoietic stem cell transplantation and chimeric antigen receptor T cell therapy (CAR-T), the prognosis of patients with acute myeloid leukemia (AML) is still generally poor.
However, immunotherapy is currently a hot topic in the treatment of hematological tumors. Extracellular adenosine triphosphate (ATP) can be converted to adenosine diphosphate (ADP) via CD39, and ADP can be converted to adenosine via CD73, which can bind to P1 and P2 receptors to exert immunomodulatory effects.
Research on the mechanism of the purinergic signaling pathway can provide a new direction for the treatment of AML, and inhibitors of this signaling pathway have been discovered by several researchers and gradually applied in the clinic. In this paper, the mechanism of the purinergic signaling pathway and its clinical application are described, revealing a new target for the treatment of AML and subsequent improvement in patient prognosis.
论文信息
- 作者
- Wang H、Wei Y、Wang N
- 第一作者单位
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.China
- 通讯作者单位
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. wangnadoris@126.com.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Purinergic signalling2025 Aug
- 原文标识
- PubMed 38446337 · DOI 10.1007/s11302-024-09997-8
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →